Development of new MDR-tuberculosis drugs

Development of New MDR-Tuberculosis Drugs

Volumn , Issue , 2010, Pages 1-98

  Vinšová, Jarmila ^a   Krátký, Martin ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85016574609     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Book

References (218)

1. Wright, A; Zignol, M. Anti-tuberculosis drug resistance in the world (fourth global report) [online]. 2008 [cited 2008-12-6]. Available from:http://www.who.int/tb/publications/2008/drs_report4_26feb08.pdf.
2. Zager, EM; McNerney, R. Multidrug-resistant tuberculosis. BMC Infect. Dis., 2008, 8, Article Number 10.
3. Jain, A; Dixit, P. Multidrug resistant to extensively drug resistant tuberculosis: What is next?. J. Biosci., 2008, 33, 605-616.
4. Dye, C; Floyd, K; Gunneberg, C; Hosseini, M; Lonnroth, K; Nathanson, E; Pantoky, A; Piatek, M; Uplekar, M; Watt, C; Williams, B; Wright, A; Zignol, M. Global tuberculosis control: Surveillance, planning, financing: WHO report 2007. 1st ed. Geneva: World Health Organization; 2007.
5. Tuberculosis facts 2008 [online]. 2008 [cited 2009-02-09]. Available from: http://www.who.int/tb/publications/2008/factsheet_april08.pdf.
6. http://www.tibotec.com/bgdisplay.jhtml?itemname=TB_disease
7. Laughon, BE. New tuberculosis drugs in development. Curr. Top. Med. Chem., 2007, 7, 463-473.
8. Blanc, L; Chaulet, P; Espinal, M; Graham, S; Grzemska, M; Harries, A; Luelmo, F; Maher, D; O’Brien, R; Raviglione, M; Rieder, H; Starke, J; Uplekar, M; Wells, C. Treatment of tuberculosis guidelines for national programmes [online]. 2008 [cited 2008-12-06]. Available from:http://whqlibdoc.who.int/hq/2003/WHO_CDS_TB_2003.313_eng.pdf.
9. Palomino, JC; Leao, SC; Ritacco, V. Tuberculosis 2007: From basic science to patient care [online]. 2007 [cited 2008-12-18]. Available from: http://www.tuberculosistextbook.com/tuberculosis2007.pdf.
10. Frequently asked questions - XDR-TB [online]. 2006 [cited 2009-02-11]. Available from: http://www.who.int/tb/challenges/xdr/faqs/en/index.html
11. Jain, A; Mondal, R. Extensively drug-resistant tuberculosis: Current challenges and threats. FEMS Immunol. Med. Microbiol, 2008, 53, 145-150.
12. Rich, M (ed.). Guidelines for the programmatic management of drugresistant tuberculosis [online]. 2008 [cited 2009-02-08]. Available from:http://whqlibdoc.who.int/publications/2008/9789241547581_eng.pdf.
13. Bardou, F; Raynaud, C; Ramos, C; Laneelle, MA; Laneelle, G. Mechanism of isoniazid uptake in Mycobacterium tuberculosis. Microbiology (UK), 1998, 144, 2539-2544.
14. Shi, R; Itagaki, N; Sugawara, I. Overview of anti-tuberculosis (TB) drugs and their resistance mechanisms. Mini Rev. Med. Chem., 2007, 7, 1177-1185.
15. Brindley, DN; Matsumur, S; Bloch, K. Mycobacterium phlei fatty acid synthetase - a bacterial multienzyme complex. Nature, 1969, 224, 666-669.
16. Vilcheze, C; Morbidoni, HR; Weisbrod, TR; Iwamoto, H; Kuo, M; Sacchettini JC; Jacobs, WR. Inactivation of the inhA-encoded fatty acid synthase II (FAS II) enoyl-acyl carrier protein reductase induces accumulation of the FAS I end products and cell lysis of Mycobacterium smegmatis. J. Bacteriol., 2000, 182, 4059-4067.
17. Petrini, B; Hoffner, S. Drug-resistant and multidrug-resistant tubercle bacilli. Int. J. Antimicrob. Agents, 1999, 13, 93-97.
18. Ramaswamy, SV; Reich, R; Dou, SJ; Jasperse, L; Pan, X; Wanger, A; Quitugua, T; Graviss, EA. Single nucleotide polymorphism in genes associated with isoniazid resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2003, 47, 1241-1250.
19. Heym, B; Zhang, Y; Poulet, S; Young, D; Cole, ST. Characterization of the katG gene encoding a catalyse-peroxidase required for the isoniazid susceptibility of Mycobacterium tuberculosis. J. Bacteriol, 1993, 175, 4255-4259.
20. Sander, P; Böttger, EC. Mycobacteria: Genetics of resistance and implications for treatment. Chemotherapy, 1999, 45, 95-108.
21. Cohen, T; Becerra, MC; Murray, MB. Isoniazid resistance and the future of drug-resistant tuberculosis. Microb. Drug Resist., 2004, 10, 280-285.
22. Telenti, A; Honore, N; Bernasconi, C; March, J; Ortega, A; Heym, B; Takiff, HE; Cole, ST. Genotypic assessment of isoniazid and rifampin resistance in Mycobacterium tuberculosis: A blind study at reference aboratory level. J. Clin. Microbiol., 1997, 35, 719-723.
23. Ramaswamy, S; Musser, JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber. Lung Dis., 1998, 79, 3-29.
24. Zhang, Y; Permar, S; Sun, ZH. Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J. Med. Microbiol., 2002, 51, 42-49.
25. Zhang, Y; Wade, MM; Scorpio, A; Zhang, H; Sun, ZH. Mode of action of pyrazinamide: Disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J. Antimicrob. Chemother., 2003, 52, 790-795.
26. Scorpio, A; Zhang, Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat. Med., 1996, 2, 662-667.
27. Scorpio, A; Lindholm-Levy, P; Heifets, L; Gilman, R; Siddiqi, S; Cynamon, M; Zhang, Y. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 1997, 41, 540-543.
28. Morlock, GP; Crawford, JT; Butler, WR; Brim, SE; Sikes, D; Mazurek, GH; Woodley, CL; Cooksey, RC. Phenotypic characterization of pncA mutants of Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2000, 44, 2291-2295.
29. Telenti, A; Philipp, WJ; Sreevatsan, S; Bernasconi, C; Stockbauer, KE; Wieles, B; Musser, JM; Jacobs, WR. The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol. Nat. Med, 1997, 3, 567-570.
30. Ramaswamy, SV; Amin, AG; Goksel, S; Stager, CE; Dou, SJ; El Sahly, H; Moghazeh, SL; Kreiswirth, BN; Musser, JM. Molecular genetic analysis of nucleotide polymorphisms associated with ethambutol resistance in human isolates of Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2000, 44, 326-336.
31. Moazed, D; Noller, HF. Interaction of antibiotics with functional sites in 16S ribosomal-RNA. Nature, 1987, 327, 389-394.
32. Liu, XQ; Gillham, NW; Boynton, JE. Chloroplast ribosomal protein gene RPS12 of Chlamydomonas reinhardtii. Wild-type sequence, mutation to streptomycin resistance and dependence, and function in Escherichia coli. J. Biol. Chem., 1989, 264, 16100-16108.
33. Gauthier, A; Turmel, M; Lemieux, C. Mapping of chloroplast mutations conferring resistance to antibiotics in Chlamydomonas: Evidence for a novel site of streptomycin resistance in the small subunit rRNA. Mol. Gen. Genet., 1988, 214, 192-197.
34. Drlica, K; Malik, M. Fluoroquinolones: Action and resistance. Curr. Top. Med. Chem., 2003, 3, 249-282.
35. Zhang, Y; Jacobs jr., R. Mechanism of drug action, drug resistance and drug tolerance in Mycobacterium tuberculosis: Expected phenotypes from evolutionary pressure from a highly successful pathogen. In:Kaufmann, HES; Rubin, E. (eds.). Handbook of Tuberculosis:Molecular Biology and Biochemistry, Weinhaim: Wiley-VCH; 2008; 323-378.
36. Flynn, JL. Imunology of tuberculosis and implications in vaccine development. Tuberculosis, 2004, 84, 93-101.
37. Ballell, L; Field, RA; Duncan, K; Young, RJ. New small-molecule synthetic antimycobacterials. Antimicrob. Agents Chemother., 2005, 49, 2153-2163.
38. Vinsova, J; Imramovsky, A; Jampilek, J; Monreal, JF; Dolezal, M. Recent advances on isoniazide derivatives. Anti-Infect. Agents Med. Chem., 2008, 7, 1-20.
39. Ventura, C; Martins, F. Application of quantitative structur-activity relationships to the modeling of antitubercular compounds. 1. The hydrazide family. J. Med. Chem, 2008, 51, 612-624.
40. Carvalho, SA; da Silva, EF; de Souza, MVN; Lourenco, MCS; Vicente, FR. Synthesis and antimycobacterial evaluation of new trans-cinnamic acid hydrazide derivatives. Bioorg. Med. Chem. Lett., 2008, 18, 538-541.
41. Imramovsky, A; Polanc, S; Vinsova, J; Kocevar, M; Jampilek, J; Reckova, Z; Kaustova, J. A new modification of anti-tubercular active molecules. Bioorg. Med. Chem., 2007, 15, 2551-2559.
42. Scior, T; Garces-Eisele, SJ. Isoniazid is not a lead compound for its pyridyl ring derivatives, isonicotinoyl amides, hydrazides, and hydrazones: A critical review. Curr. Med. Chem., 2006, 13, 2205-2219.
43. Oliveira, JS; Sousa, EHS; Basso, LA; Palaci, M; Dietze, R; Santos, DS; Moreira, IS. An inorganic iron complex that inhibits wild-type and an isoniazid-resistant mutant 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis. Chem. Commun., 2004, 3, 312-313.
44. Oliveira, JS; de Sousa, EHS; de Souza, ON; Moreira, IS; Santos, DS; Basso, LA. Slow-onset inhibition of 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis by an inorganic complex. Curr. Pharm. Design, 2006, 12, 2409-2424.
45. Shaharyar, M; Siddiqui, AA; Ali, MA; Sriram, D; Yogeeswari, P. Synthesis and in vitro antimycobacterial activity of N1-nicotinoyl-3-(4'- hydroxy-3'-methylphenyl)-5-[(sub)phenyl]-2-pyrazolines. Bioorg. Med. Chem. Lett., 2006, 16, 3947-3949.
46. Ali, MA; Yar, MS. Synthesis and antimycobacterial activity of novel 4-[5-(substituted phenyl)-1-phenyl-4,5-dihydro-1H-3-pyrazolyl]-2- methylphenol derivatives. Med. Chem. Res., 2007, 15, 463-470.
47. da Silva, PEA; Ramos, DF; Bonacorso, HG; de la Iglesia, AI; Oliveira, MR; Coelho, T; Navarini, J; Morbidoni, HR; Zanatta, N; Martins, MAP. Synthesis and in vitro antimycobacterial activity of 3-substituted 5- hydroxy-5-trifluoro[chloro]methyl-4,5-dihydro-1H-1-(isonicotinoyl) pyrazoles. Int. J. Antimicrob. Agents, 2008, 32, 139-144.
48. Ali, MA; Yar, MS; Kumar, M; Pandian, GS. Synthesis and antitubercular activity of substituted novel pyrazoline derivatives. Nat. Prod. Res., 2007, 21, 575-579.
49. Navarrete-Vazquez, G; Molina-Salinas, GM; Duarte-Fajardo, ZV; Vargas-Villarreal, J; Estrada-Soto, S; Gonzalez-Salazar, F; Hernandez-Nuneza, E; Said-Fernandez, S. Synthesis and antimycobacterial activity of 4-(5-substituted-1,3,4-oxadiazol-2-yl)pyridines. Bioorg. Med. Chem, 2007, 15, 5502-5508.
50. Sriram, D; Yogeeswari, P; Priya, DY. Antimycobacterial activity of novel N-(substituted)-2-isonicotinoylhydrazinocarbothioamide endowed with high activity towards isoniazid resistant tuberculosis. Biomed. Pharmacother., 2009, 63, 36-39.
51. Klimesova, V; Koci, J; Waisser; K; Kaustova, J; Mollmann, U. Preparation and in vitro evaluation of benzylsulfanyl benzoxazole derivatives as potential antituberculosis agents. Eur. J. Med. Chem., 2009, 44, 2286-2293.
52. Zhang, Y; Post-Martens, K; Denkin, S. New drug candidates and therapeutic targets for tuberculosis therapy. Drug Discov. Today, 2006, 11, 21-27.
53. Rothstein, DM; Hartman, AD; Cynamon, MH; Eisenstein, BI. Development potential of rifalazil. Expert Opin. Inv. Drugs, 2003, 12, 255-271.
54. Rothstein, DM; Shalish, C; Murphy, CK; Sternlicht, A; Campbell, LA. Development potential of rifalazil and other benzoxazinorifamycins. Expert Opin. Inv. Drugs, 2006, 15, 603-623.
55. Hudson, A; Imamura, T; Gutteridge, W; Kanyok, T; Nunn, P. The current anti-TB drug research and development pipeline. 1st edition. Geneva: World Health Organization; 2003.
56. Reddy, VM; Nadadhur, G; Daneluzzi, D; Dimova, V; Gangadharam, PRJ. Antimycobacterial activity of a new rifamycin derivative, 3-(4- cinnamylpiperazinyl iminomethyl) rifamycin SV (T9). Antimicrob. Agents Chemother., 1995, 39, 2320-2324.
57. Figueiredo, R; Moiteiro, C; Medeiros, MA; da Silva, PA; Ramos, D; Spies, F; Ribeiro, MO; Lourenço, MCS; Junior, IN; Gaspar, MM; Cruz, MEM, Curto, MJM; Franzblau, SG; Orozco, H; Aguilar, D; Hernandez-Pando, R; Costa, MC. Synthesis and evaluation of rifabutin analogs against Mycobacterium avium and H37Rv, MDR and NRP Mycobacterium tuberculosis. Bioorg. Med. Chem., 2009, 17, 503-511.
58. Sriram, D; Yogeeswari, P; Reddy, SP. Synthesis of pyrazinamide Mannich bases and its antitubercular properties. Bioorg. Med. Chem. Lett., 2006, 16, 2113-2116.
59. Speirs, RJ; Welch, JT; Cynamon, MH. Activity of n-propyl pyrazinoate against pyrazinamide-resistant Mycobacterium tuberculosis:Investigations into mechanism of action of and mechanism of resistance to pyrazinamide. Antimicrob. Agents Chemother., 1995, 39, 1269-1271.
60. Cynamon, MH; Speirs, RJ; Welch, JT. In vitro antimycobacterial activity of 5-chloropyrazinamide. Antimicrob. Agents Chemother., 1998, 42, 462-463.
61. Dolezal, M; Cmedlova, P; Palek, L; Vinsova, J; Kunes, J; Buchta, V; Jampilek, J; Kralova, K. Synthesis and antimycobacterial evaluation of substituted pyrazinecarboxamides. Eur. J. Med. Chem., 2008, 43, 1105-1113.
62. Tewari, N; Tiwari, VK; Tripathi, RP; Chaturvedi, V; Srivastava, A; Srivastava, R; Shukla, PK; Chaturvedi, AK; Gaikwad, A; Sinha, S; Srivastava, BS. Synthesis of galactopyranosyl amino alcohols as a new class of antitubercular and antifungal agents. Bioorg. Med. Chem. Lett., 2004, 14, 329-332.
63. Tripathi, RP; Tiwari, VK; Tewari, N; Katiyar, D; Saxena, N; Sinha, S; Gaikwad, A; Srivastava, A; Chaturvedi, V; Manju, YK; Srivastava, R; Srivastava, BS. Synthesis and antitubercular activities of bisglycosylated diamino alcohols. Bioorg. Med. Chem., 2005, 13, 5668-5679.
64. Cynamon, MH; Sklaney, M. Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis. Antimicrob. Agents Chemother., 2003, 47, 2442-2444.
65. Nuermberger, EL; Yoshimatsu, T; Tyagi, S; Williams, K; Rosenthal, I; O’Brien, RJ; Vernon, AA; Chaisson, RE; Bishai, WR; Grosset, JH. Moxifloxacin-containing regiment of reduced duration produce a stable cure in murine tuberculosis. Am. J. Respir. Crit. Care Med., 2004, 170, 1131-1134.
66. Hu, Y; Coates, AR; Mitchison, DA. Sterilizing activities of fluoroquinolones against rifampin-tolerant population of Mycobacterium tuberculosis. Antimicrob. Agents Chemother, 2003, 47, 653-657.
67. Nuermberger, EL; Rosenthal, I; Tyagi, S; Williams, KN; Almeida, D; Peloquin, CA; Bishai, WR; Grosset, JH. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrob. Agents Chemother, 2006, 50, 2621-2625.
68. Tortoli, E; Dionisio, D; Fabbri, C. Evaluation of moxifloxacin activity in vitro against Mycobacterium tuberculosis, including resistant and multidrug-resistant strains. J. Chemother., 2004, 16, 334-336.
69. Anderson, DL. Sitafloxacin hydrate for bacterial infections. Drugs Today, 2008, 44, 489-501.
70. Lai, CC; Tan, CK; Huang, YT; Chou, CH; Hung, CC; Yang, PC; Luh, KT; Hsueh, PR. Extensively drug-resistant Mycobacterium tuberculosis during a trend of decreasing drug resistance from 2000 through 2006 at a medical center in Taiwan. Clin. Infect. Dis., 2008, 47, E57-E63.
71. Dinakaran, M; Senthilkumar, P; Yogeeswari, P; China, P; Nagaraja, V; Sriram, D. Novel ofloxacin derivatives: Synthesis, antimycobacterial and toxicological evaluation. Bioorg. Med. Chem. Lett., 2008, 18, 1229-1236.
72. Senthilkumar, P; Dinakaran, M; Yogeeswari, P; Sriram, D; China, A; Nagaraja, V. Synthesis and antimycobacterial activities of novel 6- nitroquinolone-3-carboxylic acids. Eur. J. Med. Chem., 2009, 44, 345-358.
73. Senthilkumar, P; Dinakaran, M; Yogeeswari, P; China, A; Nagaraja, V; Sriram, D. Antimycobacterial activities of novel fluoroquinolones. Biomed. Pharmacother., 2009, 63, 27-35.
74. Rivers, EC; Mancera, RL. New anti-tuberculosis drugs in clinical trials with novel mechanisms of action. Drug Discov. Today, 2008, 13, 1090-1098.
75. Nam, HS; Koh, WJ; Kwon, OJ; Cho, SN; Shim, TS. Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis. Int. J. Antimicrob. Agents, 2009, 33, 92-93.
76. Prammananan, T; Chaiprasert, A; Leechawengwongs, M. In vitro activity of linezolid against multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant (XDR)-TB isolates. Int. J. Antimicrob. Agents, 2009, 33, 190-191.
77. Corti, G; Cinelli, R; Paradisi, F. Clinical and microbiologic efficacy and safety profile of linezolid, a new oxazolidinone antibiotic. Int. J. Antimicrob. Agents, 2000, 16, 527-530.
78. Erturan, Z; Uzun, M. In vitro activity of linezolid against multidrugresistant Mycobacterium tuberculosis isolates. Int. J. Antimicrob. Agents, 2005, 26, 78-80.
79. von der Lippe, B; Sandven, P; Brubakk, O. Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB) - a report of ten cases. J. Infect., 2006, 52, 92-96.
80. Park, IN; Hong, SB; Oh, YM; Kim, MN; Lim, CM; Lee, SD; Koh, Y; Kim, WS; Kim, DS; Kim, WD; Shim, TS. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis. J. Antimicrob. Chemother., 2006, 58, 701-704.
81. Fortun, J; Martin-Davila, P; Navas, E; Perez-Elias, MJ; Cobo, J; Tato, M; de la Pedrosa, EGG; Gomez-Mampaso, E; Moreno, S. Linezolid for the treatment of multidrug-resistant tuberculosis. J. Antimicrob. Chemother., 2005, 56, 180-185.
82. Swaney, SM; Aoki, H; Ganoza, MC; Shinabarger, DL. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob. Agents Chemother, 1998, 42, 3251-3255.
83. Barbachyn, MR; Hutchinson, DK; Brickner, SJ; Cynamon, MH; Kilburn, JO; Klemens, SP; Glickman, SE; Grega, KC; Hendges, SK; Toops, DS; Ford, CW; Zurenko, GE. Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity. J. Med. Chem., 1996, 39, 680-685.
84. Cynamon, MH; Klemens, SP; Sharpe, CA; Chase, S. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrob. Agents Chemother, 1999, 43, 1189-1191.
85. Vera-Cabrera, L; Castro-Garza, J; Rendon, A; Ocampo-Candiani, J; Welsh, O; Hak Choi, S; Blackwood, K; Molina-Torres, K. In vitro susceptibility of Mycobacterium tuberculosis clinical isolates to garenoxacin and DA-7867. Antimicrob. Agents Chemother., 2005, 49, 4351-4353.
86. Andries, K; Verhasselt, P; Guillemont, J; Gohlmann, HWH; Neefs, JM; Winkler, H; Van Gestel, J; Timmerman, P; Zhu, M; Lee, E; Williams, P; de Chaffoy, D; Huitric, E; Hoffner, S; Cambau, E; Truffot-Pernot, C; Lounis, N; Jarlier, V. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science, 2005, 307, 223-227.
87. Huitric, E; Verhasselt, P; Andries, K; Hoffner, SE. In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor. Antimicrob. Agents Chemother, 2007, 51, 4202-4204.
88. Koul, A; Dendouga, N; Vergauwen, K; Molenberghs, B; Vranckx, L; Willebrords, R; Ristic, Z; Lill, H; Dorange, I; Guillemont, J; Bald, D; Andries, K. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat. Chem. Biol., 2007, 3, 323-324.
89. Lounis, N; Veziris, N; Chauffour, A; Truffot-Pernot, C; Adries, K; Jarlier, V. Combinations of R207910 with drugs used to treat multidrugresistant tuberculosis have the potential to shorten treatment duration. Antimicrob. Agents Chemother, 2006, 50, 3543-3547.
90. Ibrahim, M; Andries, K; Lounis, N; Chauffour, A; Truffot-Pernot, C; Jarlier, V; Veziris, N. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. Antimicrob. Agents Chemother, 2007, 51, 1011-1015.
91. Koul, A; Vranckx, L; Dendouga, N; Balemans, W; Van den Wyngaert, I; Vergauwen, K; Goehlmann, HWH; Willebrords, R; Poncelet, A; Guillemont, J; Bald, D; Andries, K. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J. Biol. Chem., 2008, 283, 25273-25280.
92. Lenaerts, AJ; Gruppo, V; Marietta, KS; Johnson, CM; Driscoll, DK; Tompkins, NM; Rose, JD; Reynolds, RC; Orme, IM. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob. Agents Chemother, 2005, 49, 2294-2301.
93. Stover, CK; Warrener, P; VanDevanter, DR; Sherman, DR; Arain, TM; Langhorne, MH; Anderson, SW; Towell, JA; Yuan, Y; McMurray, DN; Kreiswirth, BN; Barry, CE; Baker, WR. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature, 2000, 405, 962-966.
94. Dubnau, E; Chan, J; Raynaud, C; Mohan, VP; Laneelle, MA; Yu, KM; Quemard, A; Smith, I; Daffe, M. Oxygenated mycolic acids are necessary for virulence of Mycobacterium tuberculosis in mice. Mol. Microbiol, 2000, 36, 630-637.
95. Tyagi, S; Nuermberger, E; Yoshimatsu, T; Williams, K; Rosenthal, I; Lounis, N; Bishai, W; Grosset, J. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob. Agents Chemother., 2005, 49, 2289-2293.
96. Matsumoto, M; Hashizume, H; Tomishige, T; Kawasaki, M; Tsubouchi, H; Sasaki, H; Shimokawa, Y; Komatsu, M. OPC-67683, a nitro-dihydroimidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med, 2006, 3, 2131-2144.
97. Cole, ST; Alzari, PM. Towards new tuberculosis drugs. Biochem. Soc. Trans., 2007, 35, 1321-1324.
98. Deidda, D; Lampis, G; Fioravanti, R; Biava, M; Porretta, GC; Zanetti, S; Pompei, R. Bactericidal activities of the pyrrole derivative BM212 against multidrug-resistant and intramacrophagic Mycobacterium tuberculosis strains. Antimicrob. Agents Chemother, 1998, 42, 3035-3037.
99. Biava, M; Porretta, GC; Poce, G; Deidda, D; Pompei, R; Tafi, A; Manetti, F. Antimycobacterial compounds. Optimization of the BM 212 structure, the lead compound for a new pyrrole derivative class. Bioorg. Med. Chem, 2005, 13, 1221-1230.
100. Biava, M; Porretta, GC; Deidda, D; Pompei, R; Tafi, A; Manetti, F. Antimycobacterial compounds. New pyrrole derivatives of BM212. Bioorg. Med. Chem, 2004, 12, 1453-1458.
101. Biava, M; Porretta, GC; Poce, G; Supino, S; Deidda, D; Pompei, R; Molicotti, P; Manetti, F; Botta, M. Antimycobacterial agents. Novel diarylpyrrole derivatives of BM212 endowed with high activity toward Mycobacterium tuberculosis and low cytotoxicity. J. Med. Chem, 2006, 49, 4946-4952.
102. Nikonenko, BV; Protopopova, M; Sarnala, R; Einck, L; Nacy, CA. Drug therapy of experimental tuberculosis (TB): Improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs. Antimicrob. Agents Chemother, 2007, 51, 1563-1565.
103. Jia, J; Tomaszewski, JE; Hanrahan, C; Coward, L; Noker, P; Gorman, G; Nikonenko, B; Protopopova, M. Pharmacodynamics and pharmacokinetics of SQ109, new diamine-based antitubercular drug. Br. J. Pharmacol, 2005, 144, 80-87.
104. Jia, L; Noker, PE; Coward, L; Gorman, GS; Protopopova, M; Tomaszewski, JE. Interspecies pharmacokinetics and in vitro metabolism of SQ109. Br. J. Pharmacol, 2006, 147, 476-485.
105. Protopopova, M; Hanrahan, C; Nikonenko, B; Sarnala, R; Chen, P; Gearhart, J; Einck, L; Nacy, CA. Identification of a new antitubercular drug candidate, SQ109, from combinatorial library of 1,2- ethylenediamines. J. Antimicrob. Chemother, 2005, 56, 968-974.
106. Chen, P; Gearhart, J; Protopopova, M; Einck, L; Nacy, CA. Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro. J. Antimicrob. Chemother, 2006, 58, 332-337.
107. LL-3858. Tuberculosis, 2008, 88, 126.
108. Hampton, T. TB drug research picks up the pace. JAMA, 2005, 293, 2705-2707.
109. Tomioka, H; Tatano, Y; Yasumoto, K; Shimizu, T. Recent advances in antituberculous drug development and novel drug targets. Expert Rev. Resp. Med., 2008, 2, 455-471.
110. Cole, ST; Brosch, R; Parkhill, J; Garnier, T; Churcher, C; Harris, D; Gordon, SV; Eiglmeier, K; Gas, S; Barry, CE; Tekaia, F; Badcock, K; Basham, D; Brown, D; Chillingworth, T; Connor, R; Davies, R; Devlin, K; Feltwell, T; Gentles, S; Hamlin, N; Holroyd, S; Hornby, T; Jagels, K; Krogh, A; McLean, J; Moule, S; Murphy, L; Oliver, K; Osborne, J; Quail, MA; Rajandream, MA; Rogers, J; Rutter, S; Seeger, K; Skelton, J; Squares, R; Squares, S; Sulston, JE; Taylor, K; Whitehead, S; Barrell, BG. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature, 1998, 393, 537-544.
111. Hong, X; Hopfinger, AJ. Molecular modeling and simulation of Mycobacterium tuberculosis cell wall permeability. Biomacromolecules, 2004, 5, 1066-1077.
112. Brennan, PJ; Nikaido, H. The envelope of mycobacteria. Annu. Rev. Biochem, 1995, 64, 29-63.
113. http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=glyco2&part=ch20&rendertype=figure&id=ch20.f8
114. van Rensburg, CEJ; Joone, GK; Siegel, FA; Matlola, NM; O’Sullivan, JF. In vitro investigation of the antimicrobial activities of a novel tetramethylpiperidine-substituted phenazines against Mycobacterium tubeculosis. Chemotherapy, 2000, 46, 43-48.
115. Reddy, VM; O’Sullivan, JF; Gangadharam, PRJ. Antimycobacterial activities of riminophenazines. J. Antimicrob. Chemother., 1999, 43, 615-623.
116. Matsumoto, M; Hashizume, H; Tsubouchi, H; Sasaki, H; Itotani, M; Kuroda, H; Tomishige, T; Kawasaki, M; Komatsu, M. Screening for novel antituberculosis agents that are effective against multidrug resistant tuberculosis. Curr. Top. Med. Chem., 2007, 7, 499-507.
117. Reddy, VM; Nadadhur, G; Daneluzzi, D; O’Sullivan, JF; Gangadharam, PRJ. Antituberculosis activities of clofazimine and its new analogs B4154 and B4157. Antimicrob. Agents Chemother., 1996, 633-636.
118. Schroeder, EK; de Souza, ON; Santos, DS; Blanchard, JS; Basso, LA. Drugs that inhibit mycolic acid biosynthesis in Mycobacterium tuberculosis. Curr. Pharm. Biotechnol, 2002, 3, 197-225.
119. Barry, PJ; O’Connor, TM. Novel agents in the management of Mycobacterium tuberculosis disease. Curr. Med. Chem., 2007, 14, 2000-2008.
120. Parrish, NM; Kuhajda, FP; Heine, HS; Bishai, WR; Dick, JD. Antimycobacterial activity of cerulenin and its effects on lipid biosynthesis. J. Antimicrob. Chemother., 1999, 43, 219-26.
121. Chang, Y; Fox, BG. Identification of Rv3230c as the NADPH oxidoreductase of a two-protein DesA3 acyl-CoA desaturase in Mycobacterium tuberculosis H37Rv. Biochemistry, 2006, 45, 13476-13486.
122. Chang, Y; Wesenberg, GE; Bingman, CA; Fox, BG. In vivo inactivation of the mycobacterial integral membrane stearoyl coenzyme a desaturase DesA3 by a C-terminus-specific degradation process. J. Bacteriol., 2008, 190, 6686-6696.
123. Kordulakova, J; Janin, YL; Liav, A; Barilone, N; Dos Vultos, T; Rauzier, J; Brennan, PJ; Gicquel, B; Jackson, M. Isoxyl activation is required for bacteriostatic activity against Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2007, 51, 3824-3829.
124. Phetsuksiri, B; Jackson, M; Scherman, H; McNeil, M; Besra, GS; Baulard, AR; Slayden, RA; DeBarber, AE; Barry, CE; Baird, MS; Crick, DC; Brennan, PJ. Unique mechanism of action of the thiourea drug isoxyl on Mycobacterium tuberculosis. J. Biol. Chem., 2003, 278, 53123-53130.
125. DeBarber, AE; Mdluli, K; Bosman, N; Bekker, LG; Barry, CE. Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U.S.A., 2000, 97, 9677-9682.
126. Phetsuksiri, B; Baulard, AR; Cooper, AR; Minnikin, DE; Douglas, JD; Besra, GS; Brennan, PJ. Antimycobacterial activities of isoxyl and new derivatives through the inhibition of mycolic acid synthesis. Antimicrob. Agents Chemother, 1999, 43, 1042-1051.
127. Sriram, D; Yogeeswari, P; Dinakaran, M; Thirumurugan, R. Antimycobacterial activity of novel 1-(5-cyclobutyl-1,3-oxazol-2-yl)-3-(sub)phenyl/pyridylthiourea compounds endowed with high activity toward multidrug-resistant. Mycobacterium tuberculosis. J. Antimicrob. Chemother., 2007, 59, 1194-1196.
128. Hackbarth, CJ; Chen, DZ; Lewis, JG; Clark, K; Mangold, JB; Cramer, JA; Margolis, PS; Wang, W; Koehn, J; Wu, C; Lopez, S; Withers, GIII; Gu, H; Dunn, E; Kulathila, R; Pan, SH; Porter, WL; Jacobs, J; Trias, J; Patel, DV; Weidmann, B; White, RJ; Yuan, Z. N-Alkyl urea hydroxamic acids as a new class of peptide deformylase inhibitors with antibacterial activity. Antimicrob. Agents Chemother, 2002, 46, 2752-2764.
129. Teo, JWP; Thayalan, P; Beer, D; Yap, ASL; Nanjundappa, M; Ngew, X; Duraiswamy, J; Liung, S; Dartois, V; Schreiber, M; Hasan, S; Cynamon, M; Ryder, NS; Yang, X; Weidmann, B; Bracken, K; Dick, T; Mukherjee, K. Peptide deformylase inhibitors as potent antimycobacterial agents. Antimicrob. Agents Chemother., 2006, 50, 3665-3673.
130. Pichota, A; Duraiswamy, J; Yin, Z; Keller, TH; Alam, J; Liung, S; Lee, G; Ding, M; Wang, G; Chan, WL; Schreiber, M; Maa, I; Beer, D; Ngew, X; Mukherjee, K; Nanjundappa, M; Teo, JWP; Thayalan, P; Yap, A; Dick, T; Meng, W; Xu, M; Koehn, J; Pan, SH; Clark, K; Xie, X; Shoen, C; Cynamon, M. Peptide deformylase inhibitors of Mycobacterium tuberculosis: Synthesis, structural investigations, and biological results. Bioorg. Med. Chem. Lett., 2008, 18, 6568-6572.
131. He, X; Alian, A; Stroud, R; de Montellano, PRO. Pyrrolidine carboxamides as a novel class of inhibitors of enoyl acyl carrier protein reductase from Mycobacterium tuberculosis. J. Med. Chem., 2006, 49, 6308-6323.
132. Hea, X; Alian, A; de Montellano, PRO. Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides. Bioorg. Med. Chem., 2007, 15, 6649-6658.
133. McMurry, LM; Oethinger, M; Levy, SB. Triclosan targets lipid synthesis. Nature, 1998, 394, 531-532.
134. Sullivan, TJ; Truglio, JJ; Boyne, ME; Novichenok, P; Zhang, X; Stratton, CF; Li, HJ; Kaur, T; Amin, SA; Johnson, F; Slayden, RA; Kisker, C; Tonge, PJ. High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis. ACS Chem. Biol., 2006, 1, 43-53.
135. Andrade, CH; Pasqualoto, KFM; Zaim, MH; Ferreira, EI. Rational approach in the new antituberculosis agent design: Inhibitors of InhA, the enoyl-ACP reductase from Mycobacterium tuberculosis. Rev. Bras. Cienc. Farm., 2008, 44, 167-179.
136. Lu, H; Tonge, PJ. Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway. Acc. Chem. Res., 2008, 41, 11-20.
137. Lowary, TL. Recent progress towards the identification of inhibitors of mycobacterial cell wall polysaccharide biosynthesis. Mini Rev. Med. Chem., 2003, 3, 689-702.
138. Naresh, K; Bharati, BK; Jayaraman, N; Chatterji, D. Synthesis and mycobacterial growth inhibition activities of bivalent and monovalent arabinofuranoside containing alkyl glycosides. Org. Biomol. Chem., 2008, 6, 2388-2393.
139. Subramaniam, V; Gurcha, SS; Besra, GS; Lotary, TL. Modified mannose disaccharides as substrates and inhibitors of a polyprenol monophosphomannose-dependent alpha-(1→ 6)-mannosyltransferase involved in mycobacterial lipoarabinomannan biosynthesis. Bioorg. Med. Chem., 2005, 13, 1083-1094.
140. Eoh, H; Brennan, PJ; Crick, DC. The Mycobacterium tuberculosis MEP (2C-methyl-D-erythritol 4-phosphate) pathway as a new drug target. Tuberculosis, 2009, 89, 1-11.
141. Eoh, H; Brown, AC; Buetow, L; Hunter, WN; Parish, T; Kaur, D; Brennan, PJ; Crick, DC. Characterization of the Mycobacterium tuberculosis 4-diphosphocytidyl-2-C-methyl-D-erythritol synthase:Potential for drug development. J. Bacteriol., 2007, 189, 8922-8927.
142. Parrish, NM; Ko, CG; Hughes, MA; Townsed, CA; Dick, JD. Effect of n-octanesulphonylacetamide (OSA) on ATP and protein expression in Mycobacterium bovis BCG. J. Antimicrob. Chemother, 2004, 54, 722-729.
143. Koga, T; Fukuoka, T; Doi, N; Harasaki, T; Inoue, H; Hotoda, H; Kakuta, M; Muramatsu, Y; Yamamura, N; Hoshi, M; Hirota T. Activity of capuramycin analogues against Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium intracellulare in vitro and in vivo. J. Antimicrob. Chemother., 2004, 54, 755-760.
144. Tangallapally, RP; Yendapally, R; Daniels, AJ; Lee, REB; Lee, RE. Nitrofurans as novel anti-tuberculosis agents: Identification, development and evaluation. Curr. Top. Med. Chem., 2007, 7, 509-526.
145. Tangallapally, RP; Yendapally, R; Lee, REB; Lenaerts, AJM; Lee, RE. Synthesis and evaluation of cyclic secondary amine substituted phenyl and benzyl nitrofuranyl amides as novel antituberculosis agents. J. Med. Chem, 2005, 48, 8261-8269.
146. Tangallapally, RP; Lee, REB; Lenaerts, AJM; Lee, RE. Synthesis of a new and potent analogues of anti-tuberculosis agent 5-nitro-furan-2- carboxylic acid 4-(4-benzyl-piperazin-1-yl)-benzylamide with improved bioavailability. Bioorg. Med. Chem. Lett., 2006, 16, 2584-2589.
147. Tangallapally, RP; Sun, D; Rakesh; Budha, N; Lee, REB; Lenaerts, AJM; Meibohma, B; Lee, RE. Discovery of novel isoxazolines as antituberculosis agents. Bioorg. Med. Chem. Lett., 2007, 17, 6638-6642.
148. Liu, J; Ren, HP. Tuberculosis: Current treatment and new drug development. Anti-Infect. Agents Med. Chem., 2006, 5, 331-344.
149. Ghannoum, MA; Rice, LB. Antifungal agents: Mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin. Microbiol. Rev., 1999, 12, 501-517.
150. McLean, KJ; Dunford, AJ; Neeli, R; Driscoll, MD; Munro, AW. Structure, function and drug targeting in Mycobacterium tuberculosis cytochrome P450 systems. Arch. Biochem. Biophys., 2007, 464, 228-240.
151. Mamolo, MG; Zampieri, D; Vio, L; Fermeglia, M; Ferrone, M; Pricl, S; Scialino, G; Banfi, E. Antimycobacterial activity of new 3-substituted 5-(pyridin-4-yl)-3H-1,3,4-oxadiazol-2-one and 2-thione derivatives. Preliminary molecular modeling investigations. Bioorg. Med. Chem., 2005, 13, 3797-3809.
152. McLean, KJ; Clift, D; Lewis, DG; Sabri, M; Balding, PR; Sutcliffe, MJ; Leys, D; Munro. AW. The preponderance of P450s in the Mycobacterium tuberculosis genome. Trends Microbiol., 2006, 14, 220-228.
153. Munoz-Elias, EJ; McKinney, JD. Mycobacterium tuberculosis isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence. Nat. Med., 2005, 11, 638-644.
154. Munoz-Elias, EJ; Upton, AM; Cherian, J; McKinney, JD. Role of the methylcitrate cycle in Mycobacterium tuberculosis metabolism, intracellular growth, and virulence. Mol. Microbiol., 2006, 60, 1109-1122.
155. Sharma, V; Sharma, S; Bentrup, KHZ; McKinney, JD; Russell, DG; Jacobs, WR; Sacchettini, JC. Structure of isocitrate lyase, a persistence factor of Mycobacterium tuberculosis. Nat. Struct. Biol., 2000, 7, 663-668.
156. Schloss, JV; Cleland, WW. Inhibition of isocitrate lyase by 3- nitropropionate, a reaction-intermediate analogue. Biochemistry, 1982, 21, 4420-4427.
157. Tripathi, RP; Tewari, N; Dwivedi, N; Tiwari, VK. Fighting tuberculosis:An old disease with new challenges. Med. Res. Rev., 2005, 25, 93-131.
158. Li, JM; Li, N; Zhu, DY; Wan, LG; He, YL; Yang, C. Isocitrate lyase from Mycobacterium tuberculosis promotes survival of Mycobacterium smegmatis within macrophage by suppressing cell apoptosis. Chin. Med. J., 2008, 121, 1114-1119.
159. Bi, E; Lutkenhaus, J. FtsZ ring structure associated with division in Escherichia coli. Nature, 1991, 354, 161-164.
160. Huang, Q; Tonge, PJ; Slayden, RA; Kirikae, T; Ojima, I. FtsZ: A novel target for tuberculosis drug discovery. Curr. Top. Med. Chem., 2007, 7, 527-543.
161. Ojima, I; Borella, CP; Wu, XY; Bounaud, PY; Oderda, CF; Sturm, M; Miller, ML; Chakravarty, S; Chen, J; Huang, Q; Pera, P; Brooks, TA; Baer, MR; Bernacki, RJ. Design, synthesis and structure-activity relationships of novel taxane-based multidrug resistance reversal agents. J. Med. Chem., 2005, 48, 2218-2228.
162. Huang, Q; Kirikae, T; Pepe, A; Amin, A; Respicio, L; Slayden, RA; Tonge, PJ; Ojima, I. Targeting FtsZ for antituberculosis drug discovery:Noncytotoxic taxanes as novel antituberculosis agents. J. Med. Chem., 2006, 49, 463-466.
163. White, EL; Suling, WJ; Ross, LJ; Seitz, LE; Reynolds, RC. 2-Alkoxycarbonylaminopyridines: Inhibitors of Mycobacterium tuberculosis FtsZ. J. Antimicrob. Chemother., 2002, 50, 111-114.
164. Av-Gay, Y; Everett, M. The eukaryotic-like Ser/Thr protein kinases of Mycobacterium tuberculosis. Trends Microbiol, 2000, 8, 238-244.
165. Walburger, A; Koul, A; Ferrari, G; Nguyen, L; Prescianotto-Baschong, C; Huygen, K; Klebl, B; Thompson, C; Bacher, G; Pieters, J. Protein kinase G from pathogenic mycobacteria promotes survival within macrophages. Science, 2004, 304, 1800-1804.
166. Szekely, R; Waczek, F; Szabadkai, I; Nemeth, G; Hegymegi-Barakonyi, B; Eros, D; Szokol, B; Pato, J; Hafenbradl, D; Satchell, J; Saint-Joanis, B; Cole, ST; Orfi, L; Klebl, BM; Keri, G. A novel drug discovery concept for tuberculosis: Inhibition of bacterial and host cell signalling. Immunol. Lett., 2008, 116, 225-231.
167. Dinakaran, M; Senthilkumar, P; Yogeeswari, P; Sriram, D. Antitubercular activities of novel benzothiazolo naphthyridone carboxylic acid derivatives endowed with high activity toward multidrug resistant tuberculosis. Biomed. Pharmacother., 2009, 63, 11-18.
168. Dinakaran, M; Senthilkumar, P; Yogeeswari, P; China, A; Nagaraja, V; Sriram, D. Antimycobacterial activities of novel 2-(sub)-3-fluoro/nitro-5,12-dihydro-5-oxobenzothiazolo[3,2-a]quinoline-6-carboxylic acid. Bioorg. Med. Chem., 2008, 16, 3408-3418.
169. Murugesan, D; Palaniappan, S; Perumal, Y; Arnab, C; Valakunja, N; Sriram, D. Antimycobacterial and phototoxic evaluation of novel 6- fluoro/nitro-4-oxo-7-(sub)-4H-[1,3]thiazeto[3,2-a]quinoline-3- carboxylic acid. Int. J. Antimicrob. Agents, 2008, 31, 337-344.
170. Martins, M; Viveiros, M; Ramos, J; Couto, I; Molnar, J; Boeree, M; Amaral, L. SILA 421, an inhibitor of efflux pumps of cancer cells, enhances the killing of intracellular extensively drug-resistant tuberculosis (XDR-TB). Int. J. Antimicrob. Agents, 2009, 33, 479-482.
171. Amaral, L; Martins, M; Viveiros, M. Enhanced killing of intracellular multidrug-resistant Mycobacterium tuberculosis by compounds that affect the activity of efflux pumps. J. Antimicrob. Chemother., 2007, 59, 1237-1246.
172. de Mendonqa, JD; Ely, F; Palma, MS; Frazzon, J; Basso, LA; Santos, DS. Functional characterization by genetic complementation of aroB encoded dehydroquinate synthase from Mycobacterium tuberculosis H37Rv and its heterologous expression and purification. J. Bacteriol., 2007, 189, 6246-6252.
173. Segura-Cabrera, A; Rodriguez-Perez, MA. Structure-based prediction of Mycobacterium tuberculosis shikimate kinase inhibitors by highthroughput virtual screening. Bioorg. Med. Chem. Lett., 2008, 18, 3152-3157.
174. Gupte, A; Boshoff, HI; Wilson, DJ; Neres, J; Labello, BP; Somu, RV; Xing, C; Barry, CE; Aldrich, CC. Inhibition of siderophore biosynthesis by 2-triazole substituted analogues of 5'-O-[N-(salicyl)sulfamoyl]adenosine: Antibacterial nucleosides effective against Mycobacterium tuberculosis. J. Med. Chem., 2008, 51, 7495-7507.
175. Mann, S; Ploux, O. 7,8-Diaminoperlargonic acid aminotransferase from Mycobacterium tuberculosis, a potential therapeutic target. FEBS J., 2006, 273, 4778-4789.
176. Nathan, C; Gold, B; Lin, G; Stegman, M; de Carvalho, LPS; Vandal, O; Venugopal, A; Bryk, R. A philosophy of anti-infectives as a guide in the search for new drugs for tuberculosis. Tuberculosis, 2008, 88, S25-S33.
177. Ma, YF; Stern, RJ; Scherman, MS; Vissa, VD; Yan, WX; Jones, VC; Zhang, FQ; Franzblau, SG; Lewis, WH; McNeil, MR. Drug targeting Mycobacterium tuberculosis cell wall synthesis: Genetics of dTDPrhamnose synthetic enzymes and development of a microtiter platebased screen for inhibitors of conversion of dTDP-glucose to dTDPrhamnose. Antimicrob. Agents Chemother., 2001, 45, 1407-1416.
178. Babaoglu, K; Page, MA; Jones, VC; McNeil, MR; Dong, CJ; Naismith, JH; Lee, RE. Novel inhibitors of an emerging target in Mycobacterium tuberculosis; Substituted thiazolidinones as inhibitors of dTDPrhamnose synthesis. Bioorg. Med. Chem. Lett., 2003, 13, 3227-3230.
179. Chambers, HF; Turner, J; Schecter, GF; Kawamura, M; Hopewell, PC. Imipenem for treatment of tuberculosis in mice and humans. Antimicrob. Agents Chemother., 2005, 49, 2816-2821.
180. Rastogi, N; Goh, KS; Berchel, M; Bryskier, A. In vitro activities of the ketolides telithromycin (HMR 3647) and HMR 3004 compared to those of clarithromycin against slowly growing mycobacteria at pHs 6.8 and 7.4. Antimicrob. Agents Chemother., 2000, 44, 2848-2852.
181. Falzari, K; Zhu, Z; Pan, D; Liu, H; Hongmanee, P; Franzblau, SG. In vitro and in vivo activities of macrolide derivatives against Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2005, 49, 1447-1454.
182. Dutta, NK; Mazumdarb, K; Dastidar, SG; Park, JH. Activity of diclofenac used alone and in combination with streptomycin against Mycobacterium tuberculosis in mice. Int. J. Antimicrob. Agents, 2007, 30, 336-340.
183. Dutta, NK; Mazumdar, K; Dastigar, SG; Chakrabarty, AN; Shirataki, Y; Motohashi. N. In vitro and in vivo antimycobacterial activity of an antihypertensive agent methyl-L-DOPA. In Vivo, 2005, 19, 539-545.
184. Amaral, L; Kristiansen, JE; Abebe, LS; Millett, W. Inhibition of the respiration of multi-drug resistant clinical isolates of Mycobacterium tuberculosis by thioridazine: Potential use for initial therapy of freshly diagnosed tuberculosis. J. Antimicrob. Chemother., 1996, 38, 1049-1053.
185. Amaral, L; Kristiansen, JE; Viveiros, M; Atouguia, J. Activity of phenothiazines against antibiotic-resistant Mycobacterium tuberculosis:A review supporting further studies that may elucidate the potential use of thioridazine as anti-tuberculosis therapy. J. Antimicrob. Chemother., 2001, 47, 505-511.
186. Bettencourt, MV; Bosne-David, S; Amaral, L. Comparative in vitro activity of phenothiazines against multidrug-resistant Mycobacterium tuberculosis. Int. J. Antimicrob. Agents, 2000, 16, 69-71.
187. Amaral, L; Martins, M; Viveiros, M; Molnar, J; Kristiansen, JE. Promising therapy of XDR-TB/MDR-TB with thioridazine an inhibitor of bacterial efflux pumps. Curr. Drug Targets, 2008, 9, 816-819.
188. Thanacoody, HKR. Thioridazine: Resurrection as an antimicrobial agent?. Br. J. Clin. Pharmacol., 2007, 64, 566-574.
189. Weinstein, EA; Yano, T; Li, LS; Avarbock, D; Avarbock, A; Helm, D; McColm, AA; Duncan, K; Lonsdale, JT; Rubin, H. Inhibitors of type II NADH: menaquinone oxidoreductase represent a class of antitubercular drugs. Proc. Natl. Acad. Sci. U.S.A., 2005, 102, 4548-4553.
190. Madrid, PB; Polgar, WE; Tolla, L; Tanga, MJ. Synthesis and antitubercular activity of phenothiazines with reduced binding to dopamine and serotonin receptors. Bioorg. Med. Chem. Lett., 2007, 17, 3014-3017.
191. Viveiros, M; Amaral, L. Enhancement of antibiotic activity against poly-drug resistant Mycobacterium tuberculosis by phenothiazine. Int. J. Antimicrob. Agents, 2001, 17, 225-228.
192. Bate, AB; Kalin, JH; Fooksman, EM; Amorose, EL; Price, CM; Williams, HM; Rodig, MJ; Mitchell, MO; Cho, SH; Wang, Y; Franzblau, SG. Synthesis and antitubercular activity of quaternized promazine and promethazine derivatives. Bioorg. Med. Chem. Lett., 2007, 17, 1346-1348.
193. Martins, M; Schelz, Z; Martins, A; Molnar, J; Hajos, G; Riedl, Z; Viveiros, M; Yalcin, I; Aki-Sener, E; Amaral, L. In vitro and ex vivo activity of thioridazine derivatives against Mycobacterium tuberculosis. Int. J. Antimicrob. Agents, 2007, 29, 338-340.
194. Grange, JM; Snell, NJC. Activity of bromhexine and ambroxol, semisynthetic derivatives of vasicine from the Indian shrub Adhatoda vasica, against Mycobacterium tuberculosis in vitro. J. Ethnopharmacol., 1996, 50, 49-53.
195. Pathak, AK; Pathak, V; Seitz, LE; Suling, WJ; Reynold, RC.Antimycobacterial agents. 1. Thio analogues of purine. J. Med. Chem, 2004, 47, 273-276.
196. Barrow, EW; Westbrook, L; Bansal, N; Suling, WJ; Maddry, JA; Parker, WB; Barrow, WW. Antimycobacterial activity of 2-methyladenosine. J. Antimicrob. Chemother, 2003, 52, 801-808.
197. Kamal, A; Reddy, KS; Ahmed, SK; Khan, MNA; Sinha, RK; Yadava, JS; Arorab, SK. Anti-tubercular agents. Part 3. Benzothiadiazine as a novel scaffold for anti-Mycobacterium activity. Bioorg. Med. Chem., 2006, 14, 650-658.
198. Kamal, A; Ahmed, SK; Reddy, KS; Khan, MNA; Shettya, AVCRNC; Siddardha, B; Murthy, USN; Khan, IA; Kumar, M; Sharma, S; Ram, AB. Anti-tubercular agents. Part IV: Synthesis and antimycobacterial evaluation of nitroheterocyclic-based 1,2,4-benzothiadiazine. Bioorg. Med. Chem. Lett., 2007, 17, 5419-5422.
199. Kumar, RR; Perumal, S; Senthilkumar, P; Yogeeswari, P; Sriram, D. An atom efficient, solvent-free, green synthesis and antimycobacterial evaluation of 2-amino-6-methyl-4-aryl-8-[(E)-arylmethylidene]-5,6,7,8- tetrahydro-4H-pyrano[3,2-c]pyridine-3-carbonitriles. Bioorg. Med. Chem. Lett., 2007, 17, 6459-6462.
200. Villar, R; Vicente, E; Solano, B; Perez-Silanes, S; Aldana, I; Maddry, JA; Lenaerts, AJ; Franzblau, SG; Cho, SH; Monge, A; Goldman, RC. In vitro and in vivo antimycobacterial activities of ketone and amide derivatives of quinoxaline 1,4-di-N-oxide. J. Antimicrob. Chemother., 2008, 62, 547-554.
201. Vicente, E; Villar, R; Burguete, A; Solano, B; Perez-Silanes, S; Aldana, I; Maddry, JA; Lenaerts, AJ; Franzblau, SG; Cho, SH; Monge, A; Goldman, RC. Efficacy of quinoxaline 2-carboxylate 1,4-di-N-oxide derivatives in experimetnal tuberculosis. Antimicrob. Agents Chemother., 2008, 52, 3321-3326.
202. Jaso, A; Zarranz, B; Aldana, I; Monge, A. Synthesis of new quinoxaline-2-carboxylate 1,4-dioxide derivatives as anti-Mycobacterium tuberculosis agents. J. Med. Chem., 2005, 48, 2019-2025.
203. Kumar, RR; Perumal, S; Senthilkumar, P; Yogeeswari, P; Sriram, D. A highly atom economic, chemo-, regio- and stereoselective synthesis, and discovery of spiro-pyrido-pyrrolizines and pyrrolidines as antimycobacterial agents. Tetrahedron, 2008, 64, 2962-2971.
204. Kumar, RR; Perumal, S; Senthilkumar, P; Yogeeswari, P; Sriram, D. Discovery of antimycobacterial spiro-piperidin-4-ones: An atom economic, stereoselective synthesis, and biological intervention. J. Med. Chem., 2008, 51, 5731-5735.
205. Tripathi, RP; Saxena, N; Tiwari, VK; Verma, SS; Chaturvedi, V; Manju, YK; Srivastva, AK; Gaikwad, A; Sinha, S. Synthesis and antitubercular activity of substituted phenylmethyl- and pyridylmethyl amines. Bioorg. Med. Chem., 2006, 14, 8186-8196.
206. Dwivedi, N; Tewari, N; Tiwari, VK; Chaturvedi, V; Manju, YK; Srivastava, A; Giakwad, A; Sinha, S; Tripathi, RP. An efficient synthesis of aryloxyphenyl cyclopropyl methanones: A new class of anti-mycobacterial agents. Bioorg. Med. Chem. Lett., 2005, 15, 4526-4530.
207. Katiyar, D; Tiwari, VK; Tripathi, RP; Srivastava, A; Chaturvedi, V; Srivastava, R; Srivastava, BS. Synthesis and antimycobacterial activity of 3,5-disubstituted thiadiazine thiones. Bioorg. Med. Chem., 2003, 11, 4369-4375.
208. Encarnacion-Dimayuga, R; Ramírez, MR; Luna-Herrera, J. Aerothionin, a bromotyrosine derivative with antimycobacterial activity from the marine sponge Aplysina gerardogreeni (Demospongia). Pharm. Biol., 2003, 41, 384-387.
209. van Klink, JW; Larsen, L; Perry, NB; Weavers, RT; Cook, GM; Bremer, PJ; MacKenzie, AD; Kirikae, T. Triketones active against antibioticresistant bacteria: Synthesis, structure-activity relationships, and mode of action. Bioorg. Med. Chem., 2005, 13, 6651-6662.
210. Lall, N; Meyer, JJM; Wang, Y; Bapela, NB; van Rensburg, CEJ; Fourie, B; Franzblau, SG. Characterization of intracellular activity of antitubercular constituents the roots of Euclea natalensis. Pharm. Biol., 2005, 43, 353-357.
211. Lall, N; Meyer, JJM. Inhibition of drug-sensitive and drug-resistant strains of Mycobacterium tuberculosis by diospyrin, isolated from Euclea natalensis. J. Ethnopharmacol., 2001, 78, 213-216.
212. Bapela, NB; Lall, N; Fourie, PB; Franzblau, SG; van Rensburg, CEJ. Activity of 7-methyljuglone in combination with antituberculous drugs against Mycobacterium tuberculosis. Phytomedicine, 2006, 13, 630-635.
213. Mahapatra, A; Mativandlela, SPN; Binneman, B; Fourie, PB; Hamilton, CJ; Meyer, JJM; van der Kooy, F; Houghton, P; Lall, N. Activity of 7- methyljuglone derivatives against Mycobacterium tuberculosis and as subversive substrates for mycothiol disulfide reductase. Bioorg. Med. Chem., 2007, 15, 7638-7646.
214. Newton, SM; Lau, C; Wright, CW. A review of antimycobacterial natural products. Phytother. Res., 14, 2000, 303-322.
215. Molina-Salinas, GM; Ramos-Guerra, MC; Vargas-Villarreal, J; Mata-Cardenas, BD; Becerril-Montes, P; Said-Fernandez, S. Bactericidal activity of organic extracts from Flourensia cernua DC against strains of Mycobacterium tuberculosis. Arch. Med. Res., 2006, 37, 45-49.
216. Rojas, R; Caviedes, L; Aponte, JC; Vaisberg, AJ; Lewis, WH; Lamas, G; Sarasara, C; Gilman, RH; Hammond, GB. Aegicerin, the first oleanane triterpene with wide-ranging antimycobacterial activity, isolated from Clavija procera. J. Nat. Prod., 2006, 69, 845-846.
217. Camacho-Corona, MD; Ramirez-Cabrera, MA; Gonzalez-Santiago, O; Garza-Gonzalez, E; Palacios, ID; Luna-Herrera, J. Activity against drug resistant-tuberculosis strains of plants used in Mexican traditional medicine to treat tuberculosis and other respiratory diseases. Phytother. Res., 2008, 22, 82-85.
218. McGaw, LJ; Lall, N; Meyer, JJM; Eloff, JN. The potential of South African plants against Mycobacterium infections. J. Ethnopharmacol., 2008, 119, 482-500.